Desvenlafaxine Safely Curbs Hot FlushesDesvenlafaxine Safely Curbs Hot Flushes

Desvenlafaxine (Pristiq, Pfizer) maintains its efficacy in reducing menopausal vasomotor symptoms and does so safely, according to two reports online December 24 in Menopause. Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Ob/Gyn & Women ' s Health News Source Type: news

Related Links:

Publication date: Available online 31 March 2020Source: Journal of Trace Elements in Medicine and BiologyAuthor(s): Joanna Owsianowska, Magdalena Sylwia Kamińska, Mateusz Bosiacki, Dariusz Chlubek, Beata Karakiewicz, Anna Jurczak, Marzanna Stanisławska, Katarzyna Barczak, Elżbieta Grochans
Source: Journal of Trace Elements in Medicine and Biology - Category: Biochemistry Source Type: research
This article reviews sex differences in stroke risk and presentation, with a particular emphasis on the unique risk factors women experience throughout the lifespan. RECENT FINDINGS Although prior studies suggested women have worse outcomes after stroke, it is now clear that age, prestroke functional status, and comorbidities explain many of the differences between men and women in stroke severity, functional outcomes, and mortality. Several meta-analyses and large cohort studies have evaluated the risk factors for women related to reproductive factors and found that fewer years between menarche and menopause, pregnancy...
Source: CONTINUUM: Lifelong Learning in Neurology - Category: Neurology Tags: REVIEW ARTICLES Source Type: research
(University of Jyv ä skyl ä - Jyv ä skyl ä n yliopisto) Late menopausal status is associated with an elevated level of depressive symptoms that indicate the negative dimension of mental well-being. However, menopause was not linked to positive dimensions of mental well-being in women aged 47 to 55. The results also suggest that a high level of physical activity was linked to fewer depressive symptoms, higher satisfaction with life and higher positive affectivity in menopausal women.
Source: EurekAlert! - Social and Behavioral Science - Category: International Medicine & Public Health Source Type: news
Annals of the American Thoracic Society,Volume 17, Issue 4, Page 419-420, April 2020.
Source: Annals of the American Thoracic Society - Category: Respiratory Medicine Authors: Source Type: research
Annals of the American Thoracic Society,Volume 17, Issue 4, Page 429-437, April 2020.
Source: Annals of the American Thoracic Society - Category: Respiratory Medicine Authors: Source Type: research
No abstract available
Source: Menopause - Category: OBGYN Tags: Editorials Source Type: research
No abstract available
Source: Menopause - Category: OBGYN Tags: Editorials Source Type: research
No abstract available
Source: Menopause - Category: OBGYN Tags: Editorials Source Type: research
Objective: Menopausal vasomotor symptoms (VMS) may result from altered thermoregulatory control in brain regions innervated by neurokinin 3 receptor-expressing neurons. This phase 2b study evaluated seven dosing regimens of fezolinetant, a selective neurokinin 3 receptor antagonist, as a nonhormone approach for the treatment of VMS. Methods: Menopausal women aged>40-65 years with moderate/severe VMS (≥50 episodes/wk) were randomized (double-blind) to fezolinetant 15, 30, 60, 90 mg BID or 30, 60, 120 mg QD, or placebo for 12 weeks. Primary outcomes were reduction in moderate/severe VMS frequency and severit...
Source: Menopause - Category: OBGYN Tags: Original Studies Source Type: research
Conclusion: Increased education of ob-gyn physicians related to depression during perimenopause may increase the screening and treatment of women during this phase of life.
Source: Menopause - Category: OBGYN Tags: Original Studies Source Type: research
More News: Health | Men | Menopause | Pfizer | Pristiq | Women